Literature DB >> 8385567

Malignant rhabdoid tumor. A study with two established cell lines.

S Ota1, D C Crabbe, T N Tran, T J Triche, H Shimada.   

Abstract

BACKGROUND: Malignant rhabdoid tumor (MRT), originally described as a rare renal sarcoma in childhood, has been known to express phenotypic diversity. In this study, unique characteristics of the MRT cells were investigated by using established cell lines.
METHODS: Immunocytochemical, ultrastructural, cytogenetic, and molecular (by polymerase chain reaction, PCR) analyses were done for two MRT cell lines, one of renal and one of extrarenal origin, before and after differentiation-induction with either 12-O-tetradecanoyl phorbol-13-acetate (TPA) or transretinoic acid (RA).
RESULTS: The proliferating cells in the original tumor tissues as well as in the established cell lines demonstrated neural, epithelial, and mesenchymal markers morphologically. Both cell lines had karyotypic abnormalities including chromosome 22q11.2. The cell line from the extrarenal MRT, Tm87-16, demonstrated distinct morphologic changes with neuroblastic differentiation and produced numerous neuritic processes after treatment with either TPA or RA. The cell line from the renal MRT, STM91-01, suggested schwannian differentiation but did not change morphologically after chemical induction. Both cell lines expressed c-myc, but did not express N-myc, MyoD1, tyrosine hydroxylase, or neural cell adhesion molecule (N-CAM). With PCR and immunocytochemical study, a high level of chromogranin expression was detected by the cells of Tm87-16 only after TPA induced differentiation.
CONCLUSIONS: MRT cells demonstrated diverse phenotype of neuro-ecto-mesenchymal differentiation. The results of this study suggest that MRT may be derived from a primitive pluripotential cell, such as neural crest or equivalent. MRT, therefore, might be categorized as one of the subsets of primitive neuroectodermal tumor.

Entities:  

Mesh:

Year:  1993        PMID: 8385567     DOI: 10.1002/1097-0142(19930501)71:9<2862::aid-cncr2820710930>3.0.co;2-d

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  18 in total

Review 1.  Clinicopathologic and cytogenetic analysis of malignant rhabdoid tumor of the central nervous system.

Authors:  R P Hasserjian; R D Folkerth; R M Scott; D E Schofield
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 2.  Malignant rhabdoid tumor of the colon: report of a case.

Authors:  I Nakamura; K Nakano; K Nakayama; Y Ishii; K Ohta; M Takahashi; T Yamada; K Yamaguchi; H Sakuma; A Tsuchiya; S Takenoshita
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

Review 3.  Recent advances in embryonal tumours of the central nervous system.

Authors:  Chitra Sarkar; Prabal Deb; Mehar Chand Sharma
Journal:  Childs Nerv Syst       Date:  2005-01-29       Impact factor: 1.475

4.  Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors.

Authors:  Yushui Wu; Xueqing Lun; Hongyuan Zhou; Limei Wang; Beichen Sun; John C Bell; John W Barrett; Grant McFadden; Jaclyn A Biegel; Donna L Senger; Peter A Forsyth
Journal:  Clin Cancer Res       Date:  2008-02-15       Impact factor: 12.531

5.  Malignant rhabdoid tumor of the floor of mouth: first reported case in the oral cavity of an adult.

Authors:  Stephanie L Wetzel; Stanley Kerpel; Renee F Reich; Paul D Freedman
Journal:  Head Neck Pathol       Date:  2014-07-06

6.  Genome-Wide Profiles of Extra-cranial Malignant Rhabdoid Tumors Reveal Heterogeneity and Dysregulated Developmental Pathways.

Authors:  Hye-Jung E Chun; Emilia L Lim; Alireza Heravi-Moussavi; Saeed Saberi; Karen L Mungall; Mikhail Bilenky; Annaick Carles; Kane Tse; Inna Shlafman; Kelsey Zhu; Jenny Q Qian; Diana L Palmquist; An He; William Long; Rodrigo Goya; Michelle Ng; Veronique G LeBlanc; Erin Pleasance; Nina Thiessen; Tina Wong; Eric Chuah; Yong-Jun Zhao; Jacquie E Schein; Daniela S Gerhard; Michael D Taylor; Andrew J Mungall; Richard A Moore; Yussanne Ma; Steven J M Jones; Elizabeth J Perlman; Martin Hirst; Marco A Marra
Journal:  Cancer Cell       Date:  2016-03-14       Impact factor: 31.743

7.  Rare Malignant Tumors of Clitoris-a Case Report.

Authors:  P R Venugopal; Padma Ramachandran
Journal:  Indian J Surg       Date:  2013-07-30       Impact factor: 0.656

8.  Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood.

Authors:  L B Rorke; R Packer; J Biegel
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 9.  Malignant rhabdoid tumour of the oesophagus: a case report.

Authors:  W C Ng; H T Leong; K F Ma; W L Yip; W M Suen
Journal:  J Clin Pathol       Date:  2003-09       Impact factor: 3.411

10.  Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors.

Authors:  Elizabeth M Algar; Andrea Muscat; Vinod Dagar; Christian Rickert; C W Chow; Jaclyn A Biegel; Paul G Ekert; Richard Saffery; Jeff Craig; Ricky W Johnstone; David M Ashley
Journal:  PLoS One       Date:  2009-02-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.